长春瑞滨联合参芪扶正注射液同步放疗治疗老年食管癌30例临床观察

目的 观察长春瑞滨联合参芪扶正注射液同步治疗老年食管癌的疗效及其不良反应。方法 60例老年食管鳞状细胞癌患者随机分为单纯放疗组（简称RT组）30例和长春瑞滨联合参芪扶正注射液同步放疗组（简称CRT组）30例，CRT组放疗剂量每28～30次（50.4～54.0）Gy；RT组放疗剂量每35～37次（63.0～66.6）Gy。结果CRT组和RT组患者的有效率分别为96.67%和80.00％，差异有统计学意义(P=0.044)。CRT组患者的中位生存期为23.0月，RT组患者的中位生存期为16.5月。CRT组和RT组患者的3年生存率分别为33.33％和10.00％，差异有统计学意义(P=0.028)。CRT组和RT组患者的不良反应发生率无显著差异。结论 CRT组较RT组有更好的有效率和长期生存率，且不良反应并未增加。对于老年食管癌患者，可采用长春瑞滨联合参芪扶正注射液同步放疗的治疗方法，以期获得更好的疗效及长期生存。

Clinical Observation on Vinorelbine and SFI Combined with Radiation Therapy for 30 Cases with Elderly Esophageal Cancer

Objective To investigate the therapeutical effect and side-effect of vinorelbine and Shen Qi Fu Zheng Injection(SFI) combined with Radiation Therapy for elderly esophageal cancer．Methods Sixty elderly patients with esophageal squamous cell carcinoma were randomly divided intothe radiotherapy group (RT group，n=30) and Vinorelbine and SFI combined with Radiation Therapy group(CRT group，n=30). Radiation dose was （50.4-54）Gy/(28-30) fraction in CRT group and （63-66.6）Gy/（35-37）fraction in RT group.Results    Effective rate was 96.67% in CRT group and higher than that in RT group (80.00%，P=0.044). The median survival in CRT patients was longer than that in RT patients (23.0 months vs. 16.5 months). 3-year survival rate in CRT group was increased,compared with RT group (33.33% vs. 10.00%，P=0.028).The incidence of side effects of CRT group was similar to RT group.Conclusion     CRT group had a longer survival, and acceptable toxicity,compared with RT group. For older patients, radiation therapy combined with vinorelbine and SFI was able to improve their long- term survival.